These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 12584283

  • 1. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A.
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 3. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 4. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R, Naito S, Inagaki Y, Hata T, Ishida Y, Chida Y, Takayama M, Tachibana K, Ohtsuka M, Inoue A.
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Feb; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 8. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [Abstract] [Full Text] [Related]

  • 9. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M, Shirai K, Ito K, Miyamoto T, Matsumoto A, Takenaka Y, Nakagawa K, Yamanashi T, Takamitsu Y, Nakanish T.
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B.
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [Abstract] [Full Text] [Related]

  • 13. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.
    J Nephrol; 2006 Jul; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.
    McIntyre CW, Patel V, Taylor GS, Fluck RJ.
    Nephrol Dial Transplant; 2002 Sep; 17(9):1643-8. PubMed ID: 12198217
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR, Qunibi WY.
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.